Selank, Anxiety and ADHD: What the Studies Actually Test

Selank is often discussed alongside Semax, but evidence for one peptide does not establish the effects of the other. The human Selank studies examined here mainly concern anxiety disorders. Their results need to be evaluated on that basis—not relabeled as attention-deficit/hyperactivity disorder (ADHD) evidence because they mention cognition or attention.

At a glance:

• Anxiety-study participants are not interchangeable with an ADHD study population.

• A favorable comparison on one measure does not establish superiority on every outcome.

• Russian product information and European research reports need country-specific interpretation.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. It is an educational evidence appraisal, not an ADHD treatment guide; source-access limits appear below.

1. What is Selank, and what does its Russian labeling cover?

Selank is a synthetic peptide related to tuftsin. Peptogen's published instruction sheet describes an anti-anxiety nasal-drop medicine and lists anxiety- and stress-related indications, not ADHD. The inspected version lists age under 18, pregnancy, and breastfeeding among its contraindications because relevant efficacy and safety studies were not conducted. Manufacturer-hosted Selank instruction sheet — PDF

This is an important difference from discussions of Russian pediatric Semax labeling. The two products cannot be treated as a single category with shared indications or age limits.

The manufacturer labels the linked document as a 2017 instruction. The current product-level Russian registry record was not successfully retrieved here, so this guide does not certify the latest authorization number or label revision. Manufacturer product information establishes what that document says; it does not replace independent appraisal of clinical results. Manufacturer's document listing

2. What did the Russian human anxiety studies find?

2008: a small active-comparator study

Zozulia and colleagues studied 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 medazepam. The abstract reports similar anxiety effects and additional findings concerning fatigue and psychostimulant effects. PubMed classifies the report as a randomized controlled trial, but its abstract does not establish the allocation-concealment or blinding methods. Original study abstract, 2008

“Similar” is not a formal demonstration of equivalence or noninferiority. That requires an appropriate design, a prespecified margin, and adequately precise estimates. This study also does not answer whether Selank treats ADHD.

2014: the full text gives a more mixed picture

This open-label study randomly assigned 60 adults with anxiety-spectrum disorders to Selank or phenazepam, 30 per group: 14 days of treatment and follow-up at day 21. There was no placebo group. Funding included Peptogen and an RFBR grant. Original Russian full text, 2014

Anxiety responders numbered 5 versus 7 at day 14, then 17 versus 9 at day 21 (Selank versus phenazepam), favoring Selank later (reported p = 0.037). Physical-health quality-of-life improvement did not differ significantly. Nasal dryness occurred with Selank. Results and tolerability

A short, unblinded anxiety comparison cannot establish durable ADHD benefit. Reporting only the favorable follow-up would overstate the evidence. These limitations concern design, not the study's country.

2015: a different combination question

A further report compared phenazepam alone in 30 patients with phenazepam plus Selank in 40 patients with anxiety-spectrum disorders. It is not a trial of Semax plus Selank and not an ADHD trial. Original 2015 study

Combination findings must stay attached to the actual comparator, condition, and accompanying treatment. They cannot validate a different blend sold under a similar “cognitive” description.

3. Do GABA research and brain scans establish an ADHD effect?

Volkova and colleagues' 2016 experiment examined neurotransmission-related gene expression in the frontal cortex of 30 male rats divided among Selank, GABA (gamma-aminobutyric acid), and control groups. Tissue was pooled by group and time point before analysis. The work investigated a proposed mechanism; it did not measure ADHD improvement in patients. Original open-access study and methods

Pooling is a useful detail: repeated laboratory measurements of pooled tissue are not independent clinical participants. Changes in gene expression also do not, by themselves, establish receptor-level effects or a useful clinical outcome.

The 2020 Semax/Selank imaging report studied 52 healthy participants and measured resting-state connectivity. Its reported brain-network differences are exploratory biological findings, not proof of symptom or functional improvement in ADHD. Original publisher abstract

For an ADHD claim, researchers would need to study appropriately diagnosed participants and assess symptoms, impairment, tolerability, and duration of benefit. A study can be relevant to understanding the brain without answering that clinical question.

4. What can be said about use in Europe?

Russia has its own regulatory framework; it is not part of the EU authorization system. UK NICE ADHD medication recommendations do not list Selank. The guideline's omission is not proof that nobody in the UK has used it. NICE ADHD recommendations

A Belgian laboratory report by Vanhee and colleagues identified Selank and Semax in suspicious pharmaceutical preparations submitted for analysis. This documents an analytical and enforcement context, not routine Belgian prescribing or a successful European ADHD trial. Original report, Sciensano repository

This review did not verify an EU authorization for Selank. It also did not complete a search of every national register. EMA warns that its own medicine listings do not include all nationally authorized products, so an EMA search alone cannot settle all-country status. EMA explanation and national-register directory

Distinguish three claims whenever “used in Europe” appears: sold by an online vendor, studied by a European laboratory, and authorized for a particular medical indication. They are not interchangeable.

5. What remains uncertain, especially for ADHD?

The human reports reviewed here supply limited anxiety evidence, not established ADHD efficacy. This targeted search did not identify a qualifying Selank ADHD treatment trial. That is a bounded search finding, not a claim that no unpublished, unregistered, or locally indexed work exists.

The inspected Russian label mentions unpleasant taste and possible allergic reactions. FDA separately flags inadequate safety information and potential immune-response risks from aggregation or impurities in compounded Selank acetate. Its current entry is in the withdrawn-nomination section, not a statement of safety approval. Russian label, FDA safety context

These sources do not establish the frequency of uncommon or long-term harms, safety alongside ADHD medications, or the quality of a particular research vial. Absence of a problem in a small study is not proof that the problem cannot occur.

The findings also cannot be transferred automatically to N-acetyl or amidated variants, different salts or formulations, or a Semax–Selank mixture. Material identity needs its own documentation. Read the companion Semax and Russian ADHD evidence review, our research peptide documentation checklist, and the research resource library.

Review method and source access

Sources checked September 27, 2026 included English and Russian searches for Selank/Селанк, ADHD/СДВГ, anxiety trials, and attention research. Original-study abstracts, selected methods/results/funding sections of the Russian 2014 report, the 2015 abstract and introductory/methods excerpts, the 2016 laboratory paper, manufacturer-hosted instructions, and official guidance were examined. The 2008 clinical full text and subscription-only imaging full text were not reviewed; complete independent replication and funding histories were not established.

ClinicalTrials.gov returned unrelated matches for Selank. Inspection of the returned intervention names did not identify a qualifying Selank ADHD study. This is not an exhaustive search of worldwide trial registries. Current Russian product-record verification and all-country European licensing remain incomplete. Translations and interpretation were AI-assisted, not certified. This is a focused narrative review, not a systematic review or original research paper.

ADHD treatment decisions require a qualified clinician. Do not use research materials as a substitute for prescribed care. Catalog materials are for lawful laboratory research only, not human or veterinary use; this guide supplies no dosing or administration instructions.